Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
D000328:Adult; D000368:Aged; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000378:metabolism; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D012701:Serotonin / Q000378:metabolism; D014364:Tryptophan / Q000627:therapeutic use
D010648:Phenylacetates; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D004295:Dihydroxyphenylalanine; D014364:Tryptophan; D004298:Dopamine; D006719:Homovanillic Acid